

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Daniel M. GORMAN

Application No.: not yet known

Filed: Herewith

For: MAMMALIAN RECEPTOR
PROTEINS; RELATED
REAGENTS AND METHODS

Examiner: not yet known

Art Unit: not yet known


Conf. No.: not yet known

"Express Mailing" mailing label number EL 982 851 369 US
Date of Deposit: December 29, 2003

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

by:


MELANIE LYONS

INFORMATION DISCLOSURE STATEMENT

Sir:

The materials as listed in the attached Form PTO/SB/08 are brought to the Examiner's attention pursuant to the duty of disclosure under 37 C.F.R. § 1.56, § 1.97, and § 1.98. Attached please find Form PTO/SB/08 listing references AA-AW.

References AA-AD, AF-AG, AI, AM, AP, and AR-AW, listed on the attached form PTO/SB/08 have been previously cited either by Applicants or the Examiner in the parent application, U.S. Patent Application No. 09/863,818, filing date April 23, 2001, and copies should be available there. As such, these references will not be provided absent a specific request. Enclosed are references AE, AH, AJ, AK, AL, AN, AO, and AQ.

Citation of these documents should not be construed as a representation that the documents are in fact material or are in fact prior art with respect to the instant invention. The Examiner should not make any inference relating to the relative pertinence of cited references based upon the order in which the art is presented.


Citation of these documents should not be construed as a representation that a search has been made or that more pertinent art may not be in existence.

Applicants request that the Examiner fully consider the art cited in the attached Form PTO/SB/08. Applicants further request that the Patent and Trademark Office list all such art on the front of any patent issuing from this application.

Applicants believe that no fees are due with this communication. Should this not be the case, the Commissioner is hereby authorized to debit any charges or refund any overpayments to DNAX Deposit Account No. 04-1239.

Respectfully submitted,

Date: December 29, 2003

By: 
Tom Brody
Registration No.: 46,433
Agent for Applicants

Customer No. 28008

DNAX Research, Inc.
901 California Avenue
Palo Alto, CA 94304-1104
Telephone (Switchboard): (650) 496-6400
Telephone No. (Direct): (650) 496-1244
Facsimile No.: (650) 496-1200

Enclosed:

1. WO 03/006609 (129 pages).
2. GenBank. LOCUS NM_013278 (3 pages).
3. D. HAUDENSCHILD, *et al.*, *J. Biol. Chem.* 277(6):4309-4316 (8 pages).
4. S. HURST, *et al.*, *J. Immunol.* 169:443-453, July 2002 (11 pages).
5. J. LEE, *et al.*, *J. Biol. Chem.* 276(2):1660-1664 (5 pages).
6. H. LI, *et al.*, *Proc. Natl. Acad. Sci. USA*, 97(2):773-778, January 18, 2000 (6 pages).
7. C. LOCK, *et al.*, *Nature Medicine*, 8(5):500-508, May 2002 (9 pages).
8. T.A. MOSELEY, *et al.*, *Cytokine and Growth Factor Reviews* 14:155-174, 2003 (20 pages).

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	
				Filing Date	Herewith
				First Named Inventor	Daniel M. GORMAN
				Art Unit	
				Examiner Name	
Sheet	1	of	3	Attorney Docket Number	DX01170K1

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant, Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	AA	WO 96/29408	09-26-1996	YAO, et al.		
	AB	WO 99/55865	11-04-1999	STRACHAN, et al.		
	AC	WO 01/46420	06-28-2001	CHEN, et al.		
	AD	WO 01/68859	09-20-2001	S. JING		
	AE	WO 03/006609	01-23-2003	KUESTNER, et al	Pages 8 and 84.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.⁶ Applicant is to place a check mark here if English language Translation is attached.

document under WIPO Standard ST.10 is possible. Applicant is to place a check mark here if English language translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	
				Filing Date	Herewith
				First Named Inventor	Daniel M. GORMAN
				Art Unit	
				Examiner Name	
Sheet	2	of	3	Attorney Docket Number	DX01170K1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AF	J. FERNANDO BAZAN, et al., Nature, 379:591, February 15, 1996. "A newly defined interleukin-1?"	
	AG	H. BLOECKER, et al., EMBL Database, Accession Number AL133097, November 17, 1999. Definition: Homo sapiens mRNA; cDNA DKFZp434N1928 (from clone DKFZp434N1928)	
	AH	GenBank. LOCUS NM_013278, 1048 bp, mRNA linear, PRI 04-OCT-2003 DEFINITION Homo sapiens interleukin 17C (IL17C), mRNA.	
	AI	THOMAS J. GONDA and RICHARD J. D'ANDREA, Blood, 89(2):355-369, January 15, 1997. "Activating Mutations in Cytokine Receptors: Implications for Receptor Function and Role in Disease."	
	AJ	D. HAUDENSCHILD, et al., J. Biol. Chem. 277(6):4309-4316, Published JBC Papers in Press, November 12, 2001. "Soluble and transmembrane isoforms of novel interleukin-17 receptor-like protein by RNA splicing and expression in prostate cancer."	
	AK	S. HURST, et al., J. Immunol. 169:443-453, July 2002. "New IL-17 family members promote Th1 or Th2 responses in the lung: in vivo function of the novel cytokine IL-25."	
	AL	J. LEE, et al., J. Biol. Chem. 276(2):1660-1664, Published JBC Papers in Press October 31, 2000. "IL-17E, a novel proinflammatory ligand for the IL-17 receptor homolog IL-17Rh1."	
	AM	ALEXANDER LEVITSKI, Current Opinion in Cell Biology, 8:239-244, 1996. "Targeting signal transduction for disease therapy"	
	AN	H. LI, et al., Proc. Natl. Acad. Sci. USA, 97(2):773-778, January 18, 2000. "Cloning and characterization of IL-17B and IL-17C, two new members of the IL-17 cytokine family."	
	AO	C. LOCK, et al., Nature Medicine, 8(5):500-508, May 2002. "Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis."	
	AP	M. MARRA, et al., EMBL Database, Accession Number AW107583, October 21, 1999. Definition: u191g04.y1 Sugano mouse kidney mkia Mus musculus cDNA clone IMAGE:2159478 5', mRNA sequence	
	AQ	T.A. MOSELEY, et al., Cytokine and Growth Factor Reviews 14:155-174, 2003. "Interleukin-17 family and IL-17 receptors."	
	AR	NCI-CGAP, EMBL Database, Accession Number AI861981, July 22, 1999. Definition: ty30c03.x1 NCI_CGAP_Ut2 Homo sapiens cDNA clone IMAGE:2280580 3', mRNA sequence	
	AS	DAVID H. PRESKY, et al., Proc. Natl. Acad. Sci. USA, 93:14002-14007, November 1996. "A functional interleukin 12 receptor complex is composed of two b-type cytokine receptor subunits"	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number

Filing Date

Herewith

First Named Inventor

Daniel M. GORMAN

Art Unit

Examiner Name

Sheet

3

of

3

Attorney Docket Number

DX01170K1

NON PATENT LITERATURE DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.